Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Pharmacogenetics for patient care in France: A discipline that evolves!].
Barin-Le Guellec C, Picard N, Alarcan H, Barreau M, Becquemont L, Quaranta S, Boyer JC, Loriot MA; réseau national de pharmacogénétique (RNPGx). Barin-Le Guellec C, et al. Among authors: boyer jc. Therapie. 2020 Sep-Oct;75(5):459-470. doi: 10.1016/j.therap.2019.09.006. Epub 2019 Oct 30. Therapie. 2020. PMID: 31767126 Review. French.
[Therapeutic drug monitoring].
Le Guellec C, Bentué-Ferrer D; groupe STP de la SFPT. Le Guellec C, et al. Therapie. 2010 Jan-Feb;65(1):13-5. Therapie. 2010. PMID: 20443240 French. No abstract available.
[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Loriot MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C. Boyer JC, et al. Bull Cancer. 2014 Jun;101(6):533-53. doi: 10.1684/bdc.2014.1933. Bull Cancer. 2014. PMID: 24977443 Review. French.
UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.
Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C; Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNPGx). Etienne-Grimaldi MC, et al. Among authors: boyer jc. Fundam Clin Pharmacol. 2015 Jun;29(3):219-37. doi: 10.1111/fcp.12117. Epub 2015 May 4. Fundam Clin Pharmacol. 2015. PMID: 25817555
Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx).
Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; Réseau national de pharmacogénétique (RNPGx). Picard N, et al. Among authors: boyer jc. Therapie. 2017 Apr;72(2):175-183. doi: 10.1016/j.therap.2016.09.007. Epub 2017 Jan 3. Therapie. 2017. PMID: 28153355 French. No abstract available.
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J. Etienne-Grimaldi MC, et al. Among authors: boyer jc. Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. Semin Oncol. 2017. PMID: 28923215 No abstract available.
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC. Loriot MA, et al. Among authors: boyer jc. Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Bull Cancer. 2018. PMID: 29486921 Free article. Review. French.
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delaloge S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC. Loriot MA, et al. Among authors: boyer jc. Bull Cancer. 2019 Sep;106(9):759-775. doi: 10.1016/j.bulcan.2019.04.013. Epub 2019 Jun 25. Bull Cancer. 2019. PMID: 31253356 French.
130 results